Principles of Drug Metabolism and Interactions

Phase I metabolism

•    Involves oxidation, reduction, hydrolysis

•    Primarily mediated by cytochrome P450 enzymes (CYP450)

•    Can activate, inactivate, or generate toxic metabolites

•    in elderly and liver disease, increasing risk of toxicity


Phase II metabolism

•    Involves conjugation reactions (e.g. glucuronidation, sulfation, acetylation)

•    Converts drugs into more water-soluble compounds for renal or biliary excretion

•    Generally preserves drug activity or enhances clearance


Cytochrome P450 Interactions


CYP450 Inducers enzyme activity drug levels
💡 Mnemonic: CRAP GPS

•    Carbamazepine

•    Rifampicin

•    Alcohol (chronic)

•    Phenytoin

•    Griseofulvin

•    Phenobarbital

•    St John's Wort


CYP450 Inhibitors enzyme activity drug levels
💡 Mnemonic: SICKFACES.COM

•    Sodium valproate

•    Isoniazid

•    Cimetidine

•    Ketoconazole

•    Fluconazole

•    Alcohol (acute)

•    Chloramphenicol

•    Erythromycin

•    Sulfonamides

•    Ciprofloxacin

•    Omeprazole

•    Metronidazole


Pharmacokinetic Concepts


First-pass metabolism

•    Drugs absorbed via the GI tract pass through the liver via portal circulation before entering systemic  

                                                                                                                                        circulation

•    Significant hepatic metabolism reduces bioavailability

•    Examples: propranolol, verapamil, GTN, morphine


Therapeutic index

•    Narrow therapeutic index = small gap between effective and toxic doses

•    Requires regular monitoring

•    Examples: digoxin, lithium, warfarin, theophylline, phenytoin



Clinical Implications


Drug interactions

•    Risk of toxicity: e.g. erythromycin (inhibitor) + warfarin INR bleeding

•    Efficacy: e.g. enzyme inducers reduce levels of immunosuppressants, anti-epileptics

Oral contraceptive failure

•    Due to:

o    Enzyme inducers (e.g. rifampicin, carbamazepine)

o    Malabsorption (e.g. vomiting, diarrhoea)


Examples of important drug interactions

•    Warfarin + antibiotics (e.g. erythromycin, metronidazole) INR

•    Theophylline + ciprofloxacin toxicity

•    Statins + macrolides (e.g. clarithromycin) rhabdomyolysis

•    SSRIs + tramadol serotonin syndrome

————————————————————————————————————————————————————————————————————————————————————————————————————————-

Author & Educational Disclaimer


Author:

Dr Phillip Cockrell BM FRCP DipClinEd


Dr Phillip Cockrell is a UK Consultant Physician in Internal Medicine, currently working at Queen Alexandra Hospital, Portsmouth University Hospitals NHS Trust. He has previously worked as a registrar across Intensive Care Medicine, Gastroenterology, Cardiology, Stroke Medicine, Acute Medicine, and Respiratory Medicine.


He has held senior leadership roles including Associate Clinical Director of the Acute Medical Unit, Clinical Director of Internal Medicine, and Chief of Medicine. Dr Cockrell has over 15 years’ experience in postgraduate medical education, having lectured extensively across the MRCP syllabus and contributed to MRCP revision teaching and course development.


Dr Cockrell holds a Bachelor of Medicine (BM), Fellowship of the Royal College of Physicians (FRCP), and a Diploma in Clinical Education (DipClinEd). His teaching approach is based on structured consolidation of complex medical topics to support efficient and effective revision for postgraduate examinations.


Purpose of this content:

The material on this page is intended solely for educational purposes to support revision for the MRCP (UK) Part 1 examination. It reflects examination-relevant principles of internal medicine and is designed to aid learning and pattern recognition.


Medical disclaimer:

This content is designed for postgraduate medical examination revision and does not constitute medical advice, diagnosis, or treatment guidance and must not be used as a substitute for professional clinical judgement, local guidelines, or specialist consultation. Clinical decisions should always be made in the context of individual patient circumstances and current national guidance.